The nation of Zimbabwe has declined a major US healthcare agreement worth 367 million US dollars (£272m) over five years because of Washington's request for confidential information.
The decision became public following a government memo from December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesman has since explained that the United States was seeking biological samples for scientific study and profit but was not willing to share the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for further talks to secure a agreement acceptable to both sides so the country's critical HIV programme can proceed.
Wider Implications
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court suspended a similar deal with the US following legal challenges were raised about the security of citizens' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and accountability.
Based on reports, Sixteen African countries have so far signed similar agreements, constituting more than $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy via US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its genetic material and health information over an extended period, without any equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that could result from that shared data," Mangwana explained.
"Put simply, our nation would provide the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our citizens if a future health crisis emerge."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of one-on-one deals were upending frameworks previously set up via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage future global health emergencies.
"This framework is designed to guarantee that when a country provides its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing discussions with our American counterparts on how future collaboration could be structured in a way that honours the sovereignty and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that negotiations must proceed given that a large portion of the nation's HIV programmes depended on external financing.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," the group commented.
The situation emphasises the continuing challenges between accepting vital international aid and safeguarding a country's data in an increasingly data-driven world.